Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Needham analyst Mike Matson downgraded the rating for CONMED Corporation (NYSE:CNMD) from Buy to Hold and maintained the price target of $61. Conmed shares closed at $56.95 on …
Full story available on Benzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Needham analyst Mike Matson downgraded the rating for CONMED Corporation (NYSE:CNMD) from Buy to Hold and maintained the price target of $61. Conmed shares closed at $56.95 on …
Full story available on Benzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Needham analyst Mike Matson downgraded the rating for CONMED Corporation (NYSE:CNMD) from Buy to Hold and maintained the price target of $61. Conmed shares closed at $56.95 on …Full story available on Benzinga.com Read MoreAU, CAG, CNMD, GENI, MOD, News, Top Downgrades, VG, Downgrades, Markets, Analyst Ratings, Trading Ideas, CNMD, US2074101013, AU, US0351282068, CAG, US2058871029, MOD, US6078281002, VG, US92886T2015, GENI, News, Downgrades, Markets, Analyst Ratings, Trading Ideas, Benzinga Markets
